Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In VitroE484K를 체외에서 운반하는 정통 중증 급성 호흡기 증후군 코로나바이러스 2 변이의 제한된 중화Article Published on 2021-10-132022-09-11 Journal: The Journal of Infectious Diseases [Category] MERS, SARS, 변종, 진단, [키워드] (Alpha) (Beta acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha antibody B.1.1.7 B.1.351 bamlanivimab Beta Carrying Casirivimab convalescent coronavirus coronavirus 2 E484K Imdevimab investigated less Limited monoclonal monoclonal antibodies monoclonal antibody neutralize P.2 pseudoviruses respiratory SARS-CoV-2 sera severe acute respiratory syndrome Coronavirus susceptible vaccination variant variants variants of concern Zeta [DOI] 10.1093/infdis/jiab355 PMC 바로가기 [Article Type] Article
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19COVID-19 치료를 위한 SARS-CoV-2-중화 단일클론항체Review Published on 2021-09-022022-09-11 Journal: The Cochrane database of systematic reviews [Category] SARS, 변종, 임상, [키워드] 95 % CI 95% CI 95% confidence interval Admission adverse event adverse events AEs all-cause mortality antibody approach average age B cell B cells bamlanivimab Blinding Casirivimab certainty certainty of evidence checked clinical Cochrane COVID-19 Study Register Combination combination therapy conducted coronavirus disease Coronavirus disease 2019 COVID-19 Data collection database death decrease dose Effectiveness etesevimab evaluated event Evidence excluded first test GRADE hospital Hospital admission Hospital admissions hospital discharge hospitalised Host Human identify Imdevimab IMV individual individuals with COVID-19 initial Intervention Invasive mechanical ventilation investigated lack life limitation mAb mAbs maintain moderate monoclonal antibodies monoclonal antibody Mortality NCT04427501 neutralising mAbs nine no effect non-hospitalised occurred outcome oxygen Oxygen requirement participant Participants patients with COVID-19 people with COVID-19 Placebo placebo group placebo treatment potential therapy progression Prophylactic provided Quality of life randomised controlled trial RCT reduce regdanvimab reported risk risk of bia risk ratio RoB2 SAE SAEs Sample size SARS-CoV-2 variant SARS-CoV-2 variants searched Selection Serious Adverse Event Serious Adverse Events severe symptom severe symptoms slight increase Sotrovimab submission Symptom systematic review target the placebo group treat treated Treatment treatment of COVID-19 usual care usual care alone [DOI] 10.1002/14651858.CD013825.pub2 PMC 바로가기 [Article Type] Review
Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemiaX-연관 무감마글로불린혈증 환자에서 렘데시비르 및 중화 항체 칵테일을 사용한 SARS-CoV-2 재발 치료Case Reports Published on 2021-09-012022-09-12 Journal: International Journal of Infectious Diseases [Category] SARS, 진단, [키워드] Case report Casirivimab chronic infection coronavirus disease COVID-19 disease higher risk humoral Imdevimab Immunocompromised immunodeficiency monoclonal antibodies monoclonal antibody Neutralizing antibodies neutralizing antibody outcome pandemic Patient Remdesivir SARS-CoV-2 therapeutic option Treatment X-linked XLA XLA. [DOI] 10.1016/j.ijid.2021.07.064 PMC 바로가기 [Article Type] Case Reports
COVID-19: potential therapeutics for pediatric patientsCOVID-19 : 소아 환자를위한 잠재적 치료제Review Published on 2021-08-302022-09-01 Journal: Pharmacological Reports [Category] SARS, 진단, 치료제, [키워드] Adults affected among others anti-SARS-CoV-2 antibodies bamlanivimab Casirivimab children children with COVID-19 clinical symptom COVID-19 COVID-19 patient Critical disease demonstrated develop Dexamethasone dissect distress Efficacy Efficacy and safety Evidence Hospitalized Imdevimab immunomodulatory medication indicated Like majority mechanism medication moderate moderate to severe monoclonal offer oxygen pandemic Patient patients pediatric Pediatric patient Pediatric patients pharmacokinetic proportion Randomized controlled trial RCTs Remdesivir respiratory distress SARS-CoV-2 severe disease Spike protein spread of COVID-19 Supportive treatment symptomatic patient Symptomatic patients Therapeutics Treatment ventilatory support [DOI] 10.1007/s43440-021-00316-1 PMC 바로가기 [Article Type] Review
Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484QL452R 및 T478K/E484Q를 보유한 정통 SARS-COV-2 B.1.617 변이체의 항체-매개 중화Communication Published on 2021-08-262022-09-01 Journal: Viruses [Category] MERS, SARS, 변종, 진단, [키워드] B.1 B.1.617 B.1.617.1 B.1.617.2 BNT2b2 Casirivimab Cell Cell culture circulating combination therapy convalescent convalescent sera Corona virus Delta effective Efficiency Epsilon Factor greater Imdevimab infections Kappa L452R less mAb mAbs monoclonal antibodies monoclonal antibody mRNA1273 neutralization Neutralization assay neutralize no difference performed reduced reduction SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants sera susceptibility susceptible T478K vaccination variant [DOI] 10.3390/v13091693 PMC 바로가기 [Article Type] Communication
Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19사설: COVID-19 고위험군 개인을 위한 SARS-CoV-2에 대한 노출 후 예방 중화 단일클론 항체Editorial Published on 2021-08-162022-09-11 Journal: Medical science monitor : international medical jo [Category] SARS, 변종, 진단, [키워드] accelerated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 approval approvals approved authorization bamlanivimab Casirivimab children clinical development Clinical studies clinical study coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 progression diagnostic drug editorial Effectiveness Emergency Emergency use Emergency use authorization etesevimab EUA exposure to FDA food high risk Imdevimab individual initial Mild mild to moderate Moderate COVID-19 monoclonal antibody monotherapy Neutralizing neutralizing monoclonal antibodies neutralizing monoclonal antibody Older pandemic Preclinical Prevent progression Prophylactic REGEN-COV Regulatory Regulatory Authorities respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe COVID-19 therapeutic therapy treat US Food and Drug Administration Vaccine variants of SARS-CoV-2 [DOI] 10.12659/MSM.934393 PMC 바로가기 [Article Type] Editorial
Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany중증 COVID-19 고위험 환자에서 병원 내 SARS-CoV-2 감염에 대한 단일클론항체 요법 사용: 독일 3차 병원의 경험Brief Report Published on 2021-07-092022-09-12 Journal: Infection [Category] SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus antibody asymptomatic patient asymptomatic patients bamlanivimab Casirivimab characterized coronavirus disease Coronavirus-2 COVID-19 cross-sectional Disease progression Germany high risk hospital Imdevimab Infection monoclonal monoclonal antibodies monoclonal antibody Monoclonal spike antibodies Mortality nosocomial outcome Patient Population Retrospective study SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV2 severe disease significant decrease supplementary material therapy Treatment [DOI] 10.1007/s15010-021-01657-y PMC 바로가기 [Article Type] Brief Report
Emergent Inpatient Administration of Casirivimab and Imdevimab Antibody Cocktail for the Treatment of COVID-19 PneumoniaInternal Medicine Published on 2021-05-272022-10-31 Journal: Cureus [Category] COVID-19, [키워드] acute respiratory syndrome antibody Casirivimab Clinical symptoms cocktail complications coronavirus coronavirus 2 correlated COVID-19 discharged drastic Dyspnea highest hospital hospitalized patients IgM Imdevimab Immunoglobulin increased risk Inpatient low-dose male Medical conditions moderate monoclonal antibodies monoclonal antibody combination Mortality mortality rate Patient patients Pneumonia recent reduce regimen REGN-CoV2 Research SARS-CoV-2 SARS-COV-2 infection seronegative Symptom Viral load worsening [DOI] 10.7759/cureus.15280 PMC 바로가기 [Article Type] Internal Medicine
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomizationUPMC OPTIMISE-C19(COVID-19에 대한 평가를 통한 단일 클론 항체의 치료 및 영향 최적화) 시험: 반응 적응형 무작위 배정이 포함된 개방형, 실용적, 비교 효과 플랫폼 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2021-05-252022-09-01 Journal: Trials [Category] SARS, 변종, 임상, 진단, [키워드] adaptive Administered administration aggregate authorization bamlanivimab Bayesian blinded Blinding calculated captures Casirivimab collected Comorbidities comparator composite endpoint Course COVID-19 criteria dependent on determine determined by dissemination distribution Dosing drug Effectiveness effort element eligibility criteria Emergency emergency department Emergency Departments etesevimab EUA evaluate evaluated FDA Final Follow-up food futility Government high risk hospital Hospitalization Hospitalized Identifier Imdevimab Impact include increase in inferiority infusion Intervention investigator investigators mAbs manuscript medical record Mild mild to moderate Mild to moderate COVID-19 Moderate COVID-19 monoclonal antibodies monoclonal antibody monotherapy number obese objective Open-label outcome outcome assessor outcome assessors oxygen pandemic participant Patient physician Platform trial Pragmatic pragmatic trial Primary outcome protocol provide random random allocation randomised randomised controlled trial randomization reached receive recorded recruitment routine clinical care Sample Sample size SARS-CoV-2 variant SARS-CoV-2 variants severe COVID-19 statistical statistical inference status Study protocol submission supplementary material supply sustained Symptoms System the patient the United State therapeutic Treatment treatment of COVID-19 Trial Trial registration United States US Food and Drug Administration Version Volume website [DOI] 10.1186/s13063-021-05316-3 PMC 바로가기 [Article Type] Letter
SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesArticle Published on 2021-04-292022-10-06 Journal: Cell [Category] SARS, 진단, [키워드] Alter antibodies antibody B.1.1.7 B.1.351 bamlanivimab blockade Brazil camostat Casirivimab cell interaction convalescent COVID-19 patient COVID-19 COVID-19 pandemic effort Entry inhibitor escape health system host cell Host cell entry human cell implication individuals inhibited inhibitor less Mutation neutralization neutralizing antibody neutralizing antibody responses P.1 P.1 variant pandemic plasma Protein pseudoparticles recombinant SARS-CoV-2 SARS-CoV-2 variant sera soluble ACE2 South Africa Spike protein Spread susceptible Treatment variant variants variants of concern viral spike VoC [DOI] 10.1016/j.cell.2021.03.036 PMC 바로가기 [Article Type] Article